FirstGroup acquires Shropshire-based Lakeside Group

FirstGroup

FirstGroup plc (LON:FGP) has announced that it has acquired Shropshire-based Lakeside Group comprising well recognised local brands Lakeside Coaches, Merediths Coaches and A. T. Brown Coaches.

  • FirstGroup has acquired Lakeside Group, a profitable, well-established Shropshire and Cheshire-based company that provides school, B2B and B2C private hire services, with a fleet of c.145 buses and coaches
  • Complementing the recent additions to the First Bus portfolio, this strategic acquisition will allow us to grow our coaching business and offers the potential to increase our presence in the West Midlands

Lakeside operates a fleet of c.145 buses and coaches of various sizes primarily from a central, owned depot in Ellesmere, Shropshire and from five smaller depots – one owned in Shrewsbury and the others leased – in Shropshire, Telford and South Cheshire.

The majority of Lakeside’s revenue is derived from school and private hire contracts, with the remaining revenue coming from tours, a small local bus operation (under contract to Shropshire County Council) and B2B operations. The business has grown significantly over recent years, both organically and inorganically, and has retained strong levels of profitability. For the year ended 31 March 2024, Lakeside delivered revenues of c.£12.5m and EBIT of c.£2.5m.

Neal Hall, the Managing Director of Lakeside, will continue to manage the business on a day-to-day basis going forward. Gareth Davies, the owner of Lakeside, will continue to lead the business and will join First Bus to support the ongoing development of its wider coaching strategy.

The acquisitions we have made in recent years, in line with our stated strategy to grow and diversify the First Bus portfolio, now represent combined annualised revenues of c.£100m and EBIT of c.£13m and we continue to evaluate a pipeline of organic and inorganic growth opportunities.

Graham Sutherland, FirstGroup Chief Executive Officer said:

“The acquisition of Lakeside, a profitable business with excellent growth potential, builds on our recent acquisitions in First Bus. The addition to our portfolio will not only grow our position in adjacent services, but it will also allow us to enter new regions which is key to the overall First Bus strategy.”

Share on:
Find more news, interviews, share price & company profile here for:

    Global Opportunities Trust reports 11.9% one year share price return to 31 August

    Global Opportunities Trust has released its August 2025 factsheet, reporting a 12-month NAV increase of 8.8% and a share price gain of 11.8%.

    Dekel Agri-Vision reports 24.5% revenue growth and break-even net profit in H1 2025

    Dekel Agri-Vision posted a stronger performance for the six months ended 30 June 2025, with Group revenue up 24.5% to €23.9m and EBITDA rising 10.7% to €3.1m.

    Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

    Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event.

    Quadrise signs addendum with Valkor to re-phase payments and MMU deliveries

    Quadrise has agreed an addendum to its Site License and Supply Agreement with Valkor Technologies in Utah. The revised terms re-phase the US$1.0 million licence fee through to June 2026 and adjust delivery schedules for Multifuel Manufacturing Units.

    Ampeak Energy reports interim results and financial close of first battery project

    Ampeak Energy has published its unaudited interim results for the six months ended 30 June 2025. The Group focused on achieving financial close of the 240 MWh AW1 battery project at Uskmouth, which was completed in August 2025.

    Nuformix to present NXP002 data at ERS Congress 2025

    Nuformix will attend the European Respiratory Society Congress in Amsterdam from 28 September 2025, where it will present new findings from its lead programme, NXP002, an inhaled treatment for idiopathic pulmonary fibrosis.

      Search

      Search